Scientists Identify Key Trigger of Crohn's Disease Scarring in Gut
Researchers have made a significant breakthrough in understanding Crohn's disease, identifying what drives the development of scar tissue in the intestines of patients. This discovery could pave the way for new treatments specifically targeting fibrosis, a serious complication of the inflammatory bowel condition.
Immune Cell Clusters Stimulate Scar Tissue Formation
Scientists from the University of Edinburgh-led research team found clusters of immune cells in the gut that appear to stimulate nearby cells to generate excess scar tissue, known medically as fibrosis. Crohn's disease is a long-term inflammatory condition affecting the digestive tract, and over time, persistent inflammation can lead to fibrosis where excess collagen builds up in the bowel wall.
This scarring causes the intestine to narrow and become blocked, often necessitating surgical intervention. The research team analysed intestinal tissue samples from Crohn's disease patients with fibrosis, focusing particularly on the ileum – the final part of the small intestine where the disease most commonly develops.
Advanced Techniques Reveal Cellular Interactions
Using both archived intestinal tissue samples and fresh samples analysed with cutting-edge single-cell RNA sequencing technology, researchers examined structural changes across different layers of the bowel wall. They discovered significantly increased fibrosis and immune cell infiltration in Crohn's disease tissue compared with normal tissue.
The submucosa – a deeper layer of the bowel wall – showed particularly high levels of scarring, indicating it may play a crucial role in the early stages of fibrosis development. Further analysis revealed that clusters of immune cells, known as Crohn's lymphoid aggregates, interact with groups of endothelial cells that normally line blood vessels.
Dr Michael Glinka, research fellow at the University of Edinburgh, explained: "Our findings highlight previously unrecognised interactions between immune cells, endothelial cells and collagen-producing cells in Crohn's disease. By combining traditional pathology with single-cell transcriptomics, we were able to confirm these changes using two independent approaches and uncover biological signalling pathways that may provide new therapeutic targets."
Potential for Targeted Fibrosis Treatments
The research suggests that endothelial cells form distinctive structures surrounding the Crohn's lymphoid aggregates, with signalling interactions between these clusters and nearby cells responsible for producing collagen. This indicates they may actively promote fibrosis development.
Dr Shahida Din, consultant gastroenterologist at NHS Lothian and honorary senior clinical lecturer at the University of Edinburgh, emphasised: "Fibrosis remains one of the most challenging complications of Crohn's disease because current treatments primarily target inflammation rather than the scarring itself. Understanding the cellular signalling pathways that link immune activity to collagen production could help guide the development of therapies aimed at preventing or slowing fibrosis."
Hope for Future Treatment Approaches
The research, published in The Journal of Pathology, was conducted through a UK-wide collaboration of researchers and clinicians with funding support from the Leona M and Harry B Helmsley Charitable Trust. The findings offer hope for developing treatments that specifically address fibrosis rather than just inflammation.
Catherine Winsor, director of service, research and evidence at the charity Crohn's & Colitis UK, commented: "People who live with Crohn's often tell us how much fibrosis and scarring can affect their lives, yet it's something current treatments don't address. This early research is really exciting because it helps us to understand what drives that scarring and where new treatments could make a difference. It brings real hope that, in the future, we might be able to treat not just inflammation, but the lasting damage Crohn's can cause."
The University of Edinburgh-led team hopes these latest findings will help pinpoint therapeutic targets that could be explored to interrupt the scarring process and develop treatments specifically aimed at fibrosis, potentially reducing the need for surgery among Crohn's disease patients.
